RedDrop Dx, Inc.

RedDrop Dx, Inc. is a US-based company specializing in innovative capillary blood sampling technology, enabling pain-free at-home blood collection to improve patient experience and healthcare efficiency. Founded in 2022 and headquartered in Fort Collins, US, RedDrop Dx, Inc. focuses on developing convenient blood sampling solutions.

The company's latest funding round was a SEED round in December 2025, raising USD 5. 00 mn from investors including Innosphere Ventures, Stout Street Capital, and Breakthrough Venture Capital. The total amount raised by the company to date is USD 5. 00 mn.

RedDrop Dx specializes in innovative capillary blood sampling technology designed to facilitate at-home and pain-free blood collection. The company's flagship product, the RedDrop™ device, allows patients to collect blood samples with minimal discomfort, utilizing a one-finger activation mechanism that provides audible and visual feedback for ease of use. This technology is particularly beneficial for healthcare providers, clinical laboratories, and researchers, enabling them to obtain high-quality blood samples efficiently and reliably. RedDrop’s products cater to diverse end users, including patients seeking convenient blood collection methods and healthcare professionals aiming for improved sample integrity and volume.

The company serves markets across the United States, focusing on both direct-to-consumer sales and partnerships with healthcare providers and laboratories to enhance the accessibility of their sampling solutions. RedDrop Dx generates revenue through direct sales of its blood sampling devices and related products, facilitating transactions primarily through B2B partnerships and direct-to-consumer channels. Clients, which include healthcare institutions and individual patients, purchase the RedDrop™ device alongside consumables, such as the specialized 1mL tubes designed for high-throughput laboratories. These transactions are structured to promote scalability, with a focus on meeting the needs of both high-volume labs and individual users.

The company positions its technology as a solution for enhancing efficiency in blood collection, thus attracting a clientele that values streamlined, pain-free sampling experiences. Specific pricing plans for the devices and consumables are tailored to reflect their innovative design and functionality, although detailed pricing information is not publicly available. In December 2025, RedDrop Dx, Inc. secured USD 5.

00 mn in SEED funding, which will be directed towards expanding manufacturing capacity, building commercial partnerships, and developing its platform for decentralized clinical trials, telehealth diagnostics, and large-scale health programs. The company plans to enhance its product offerings and aim for new geographic markets to improve accessibility to its innovative blood sampling devices.